

**2021 Multiple Sclerosis Updates: A Focus on New and Emerging Therapies, Best Practices in Clinical Management, and Key Considerations During the COVID-19 Era**  
**Tweetorial #2 References**

**Tweet 4**

Ntranos A, Lublin F. Diagnostic criteria, classification and treatment goals in multiple sclerosis: the chronicles of time and space. *Curr Neurol Neurosci Rep.* 2016;16:90. <https://doi.org/10.1007/s11910-016-0688-8>

**Tweet 6**

The PRISMS (Prevention of Relapses and Disability by Interferon- $\beta$ -1a Subcutaneously in Multiple Sclerosis) Study Group. PRISMS-4: Long-term efficacy of interferon- $\beta$ -1a in relapsing MS. *Neurology.* 2001;56:1628-1636. <https://doi.org/10.1212/WNL.56.12.1628>

**Tweet 8**

Lucchetta RC, Tonin FS, Borba HHL, et al. Disease-modifying therapies for relapsing–remitting multiple sclerosis: A network meta-analysis. *CNS Drugs.* 2018;32:813–826. <https://doi.org/10.1007/s40263-018-0541-5>

Hauser SL, Cree BAC. Treatment of multiple sclerosis: A review. *Am J Med.* 2020;133(12):1380-1390. <https://doi.org/10.1016/j.amjmed.2020.05.049>

Giovannoni G, Lang S, Wolff R, et al. A systematic review and mixed treatment comparison of pharmaceutical interventions for multiple sclerosis. *Neurol Ther.* 2020;9:359–374. <https://doi.org/10.1007/s40120-020-00212-5>

**Tweet 10**

Harding K, Williams O, Willis M, et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. *JAMA Neurol.* 2019;76(5):536-541. <https://doi.org/10.1001/jamaneurol.2018.4905>

He A, Merkel B, Brown JW, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. *The Lancet Neurol.* 2020;19(4):307-316. [https://doi.org/10.1016/S1474-4422\(20\)30067-3](https://doi.org/10.1016/S1474-4422(20)30067-3)

**Tweet 11**

Fox RJ, Cosenza C, Cripps L, et al. A survey of risk tolerance to multiple sclerosis therapies. *Neurol.* 2019;92(14):1634-1642. <https://doi.org/10.1212/WNL.0000000000007245>

## Glossary

1L, First-line  
CNS, central nervous system  
DMF, dimethyl fumarate  
DMT, disease-modifying therapies  
DRF, diroximel fumarate  
Dx, diagnosis  
EIT, early intensive treatment  
ESC, escalation therapy  
GA, glatiramer acetate  
GI, gastrointestinal  
IFN, interferon  
LT, long-term  
MRI, magnetic resonance imaging  
MMF, mycophenolate mofetil  
MS, multiple sclerosis  
NP, nurse practitioner  
PA, physician assistant  
Peg, pegylated  
PML, progressive multifocal leukoencephalopathy  
Pharm, pharmacist  
QOL, quality of life  
RN, registered nurse  
RT, randomized trial  
RRMS, relapsing-remitting multiple sclerosis  
S1P1, sphingosine-1-phosphate modulators  
S1PR, sphingosine-1-phosphate receptor  
Tx, treatment  
Y, year  
YO, year-old  
YOA, years of age

## Drugs: Generic (Trade) Names

cladribine (Leustatin)  
ozanimod (Zeposia)  
teriflunomide (Aubagio)  
alemtuzumab (Lemtrada)  
natalizumab (Tysabri)